Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Merus N-V stock | $29.25

Learn how to easily invest in Merus N-V stock.

Merus N.V is a biotechnology business based in the US. Merus N-V shares (MRUS) are listed on the NASDAQ and all prices are listed in US Dollars. Merus N-V employs 93 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Merus N-V

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MRUS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Merus N-V stock price (NASDAQ: MRUS)

Use our graph to track the performance of MRUS stocks over time.

Merus N-V shares at a glance

Information last updated 2021-10-17.
Latest market close$29.25
52-week range$11.19 - $31.80
50-day moving average $25.41
200-day moving average $22.15
Wall St. target price$35.29
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.65

Buy Merus N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Merus N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Merus N-V price performance over time

Historical closes compared with the close of $29.25 from 2021-10-18

1 week (2021-10-11) -5.61%
1 month (2021-09-17) 14.12%
3 months (2021-07-20) 63.77%
6 months (2021-04-20) 32.59%
1 year (2020-10-19) 123.28%
2 years (2019-10-18) 78.24%
3 years (2018-10-19) 80.56%
5 years (2016-10-19) 57.68%

Merus N-V financials

Revenue TTM $38.3 million
Gross profit TTM $-40,097,000
Return on assets TTM -17.66%
Return on equity TTM -55.47%
Profit margin -231.19%
Book value $5.70
Market capitalisation $1.2 billion

TTM: trailing 12 months

Shorting Merus N-V shares

There are currently 2.1 million Merus N-V shares held short by investors – that's known as Merus N-V's "short interest". This figure is 1.8% down from 2.1 million last month.

There are a few different ways that this level of interest in shorting Merus N-V shares can be evaluated.

Merus N-V's "short interest ratio" (SIR)

Merus N-V's "short interest ratio" (SIR) is the quantity of Merus N-V shares currently shorted divided by the average quantity of Merus N-V shares traded daily (recently around 121936.89095128). Merus N-V's SIR currently stands at 17.24. In other words for every 100,000 Merus N-V shares traded daily on the market, roughly 17240 shares are currently held short.

However Merus N-V's short interest can also be evaluated against the total number of Merus N-V shares, or, against the total number of tradable Merus N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Merus N-V's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Merus N-V shares in existence, roughly 50 shares are currently held short) or 0.08% of the tradable shares (for every 100,000 tradable Merus N-V shares, roughly 80 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Merus N-V.

Find out more about how you can short Merus N-V stock.

Merus N-V share dividends

We're not expecting Merus N-V to pay a dividend over the next 12 months.

Merus N-V share price volatility

Over the last 12 months, Merus N-V's shares have ranged in value from as little as $11.19 up to $31.8. A popular way to gauge a stock's volatility is its "beta".

MRUS.US volatility(beta: 0.78)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Merus N-V's is 0.7788. This would suggest that Merus N-V's shares are less volatile than average (for this exchange).

Merus N-V overview

Merus N. V. , a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat autoimmune disease. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication.

Frequently asked questions

What percentage of Merus N-V is owned by insiders or institutions?
Currently 7.931% of Merus N-V shares are held by insiders and 78.133% by institutions.
How many people work for Merus N-V?
Latest data suggests 93 work at Merus N-V.
When does the fiscal year end for Merus N-V?
Merus N-V's fiscal year ends in December.
Where is Merus N-V based?
Merus N-V's address is: Yalelaan 62, Utrecht, Netherlands, 3584 CM
What is Merus N-V's ISIN number?
Merus N-V's international securities identification number is: NL0011606264
What is Merus N-V's CUSIP number?
Merus N-V's Committee on Uniform Securities Identification Procedures number is: N5749R100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site